Latest News in the pharma Industry

Policy & Regulation

Indian Patent Office Grants First Compulsory License to Generic Company

Indian Patent Office Grants First Compulsory License to Generic Company

14 Mar 2012

India's Natco Pharma has been granted a compulsory license to sell a generic version of Bayer's patented cancer drug Nexavar.

Read more 
EMA Launches Electronic Application Form Pilot

EMA Launches Electronic Application Form Pilot

13 Mar 2012

The pilot allows pharmaceutical companies to apply for initial marketing authorisation applications for human medicines, and variation and renewal applications for human and veterinary medicines, using an interactive PDF form.

Read more 
Regeneron & Bayer Confirm Austalian Clearance of Eylea

Regeneron & Bayer Confirm Austalian Clearance of Eylea

13 Mar 2012

Bayer HealthCare has received Australian regulatory approval for eye drug Eylea, for the treatment of neovascular (wet) age-related macular degeneration.

Read more 
Arena Seeks European Marketing Approval for Lorcaserin

Arena Seeks European Marketing Approval for Lorcaserin

9 Mar 2012

Arena Pharmaceuticals has filed a Marketing Authorisation Application with the European Medicines Agency for the drug. The firm expects the agency to accept it later this month.

Read more 
FDA Accepts Eisai's Resubmission of Perampanel NDA

FDA Accepts Eisai's Resubmission of Perampanel NDA

6 Mar 2012

The FDA has accepted for review Eisai's resubmission of the New Drug Application for perampanel, an investigational drug for the treatment of partial-onset seizures associated with epilepsy.

Read more 
EMA Publishes Updated Set of Mandatory Article 57(2) Requirements for Marketing Authorisation Holders

EMA Publishes Updated Set of Mandatory Article 57(2) Requirements for Marketing Authorisation Holders

6 Mar 2012

Article 57(2) of the new pharmacovigilance legislation requires the Agency to establish lists of all human medicines authorised in the European Union (EU), based on structured data submitted by the marketing authorisation holders of these medicines.

Read more 
EMA Publishes List of Human Medicines under Evaluation

EMA Publishes List of Human Medicines under Evaluation

2 Mar 2012

The list only includes medicines whose applications have been validated. The Agency will update this information every month following the plenary meeting of the CHMP.

Read more 
India Plans to Frame Prescription Guidelines to Promote Rational Use of Drugs

India Plans to Frame Prescription Guidelines to Promote Rational Use of Drugs

29 Feb 2012

The proposed prescription guidelines will be made applicable not only in the government centres that are extending treatment for HIV and TB, but also for the private health facilities and providers.

Read more 
EC Approves Glivec Label Update

EC Approves Glivec Label Update

29 Feb 2012

The European Commission approved an update to the Glivec (imatinib) label to include 36 months of treatment with the drug following surgery for adults with KIT (CD117-positive) gastrointestinal stromal tumors (GIST).

Read more 
FDA Issues Draft Guidance on Heparin

FDA Issues Draft Guidance on Heparin

27 Feb 2012

The guidance is intended to alert manufacturers of APIs, pharmaceutical and medical device manufacturers of finished products, re-packers, and others on the potential risk of crude heparin contamination.

Read more 
EU Approves Skin Cancer Medicine Zelboraf

EU Approves Skin Cancer Medicine Zelboraf

23 Feb 2012

Zelboraf (vemurafenib), manufactured by Roche, has been approved by the European Commission, for treating patients with BRAF V600 mutationpositive unresectable or metastatic melanoma.

Read more 
AstraZeneca Receives EU Approval for Thyroid Cancer Treatment Caprelsa

AstraZeneca Receives EU Approval for Thyroid Cancer Treatment Caprelsa

23 Feb 2012

The approval is based on a Phase III trial that showed a 54% reduction in the risk of disease progression amongst the 331 patients involved in comparison to placebo.

Read more